Stocks › BNTX
BioNTech SE
BNTX·Nasdaq·
Germany·USD
Germany·USD$95.73
-1.91 (-1.96%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
BNTX
BioNTech SE · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
BNTXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of BNTX by members of U.S. Congress · 8 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Val T. HoyleHouse · D · OR |
BNTXBioNTech SE · Stock |
Sale $1,001 - $15,000 |
Sep 12, 2025 | Aug 7, 2025 | Filing ↗ |
 Josh GottheimerHouse · D · NJ |
BNTXBioNTech SE · Stock |
Sale $1,001 - $15,000 |
Oct 3, 2024 | Sep 3, 2024 | Filing ↗ |
| Josh GottheimerHouse · D · NJ |
BNTXBioNTech SE · Stock |
Sale $1,001 - $15,000 |
Sep 11, 2024 | Aug 30, 2024 | Filing ↗ |
| Josh GottheimerHouse · D · NJ |
BNTXBioNTech SE · Stock |
Purchase $1,001 - $15,000 |
May 15, 2024 | Apr 15, 2024 | Filing ↗ |
| Josh GottheimerHouse · D · NJ |
BNTXBioNTech SE · Stock |
Sale $1,001 - $15,000 |
Apr 7, 2024 | Mar 14, 2024 | Filing ↗ |
| Josh GottheimerHouse · D · NJ |
BNTXBioNTech SE · Stock |
Purchase $1,001 - $15,000 |
Jan 7, 2024 | Dec 6, 2023 | Filing ↗ |
| Josh GottheimerHouse · D · NJ |
BNTXBioNTech SE · Stock |
Purchase $1,001 - $15,000 |
Jan 7, 2024 | Dec 7, 2023 | Filing ↗ |
| Josh GottheimerHouse · D · NJ |
BNTXBioNTech SE · Stock |
Purchase $1,001 - $15,000 |
Jan 7, 2024 | Dec 5, 2023 | Filing ↗ |
Whale Activity
Position changes in BNTX reported for 2026-06-30 by 8 tracked institutional filers
- Increased3
- New2
- Held0
- Decreased1
- Closed1
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 1.9M | $172.6M | increased |
| D. E. Shaw & Co., Inc. | 417.4K | $38.8M | increased |
| CITADEL ADVISORS LLC | 364.6K | $33.9M | decreased |
| Point72 Asset Management, L.P. | 327.2K | $30.4M | new |
| TWO SIGMA INVESTMENTS, LP | 292.6K | $27.2M | increased |
| Palo Alto Investors LP | 19.6K | $1.8M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 204 | $19K | new |
| Millennium Management LLC | 0 | $0 | closed |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by BNTX insiders, by quarter · Form 4
Recent Insider Transactions
24 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Sahin UgurChief Executive Officer | Sale | −21.0K | $96.81 | $2.0M | Oct 6, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −72.0K | $97.23 | $7.0M | Oct 5, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −17.0K | $96.72 | $1.6M | Oct 2, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −17.0K | $97.46 | $1.7M | Oct 1, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −32.0K | $98.12 | $3.1M | Sep 30, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −34.0K | $98.26 | $3.3M | Sep 29, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −34.0K | $98.47 | $3.3M | Sep 28, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −27.0K | $98.69 | $2.7M | Sep 25, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −39.0K | $98.99 | $3.9M | Sep 24, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −30.0K | $99.40 | $3.0M | Sep 23, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −46.0K | $100.72 | $4.6M | Sep 22, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −33.0K | $97.81 | $3.2M | Sep 21, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −30.0K | $96.22 | $2.9M | Sep 18, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −34.0K | $98.60 | $3.4M | Sep 17, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −15.0K | $96.09 | $1.4M | Sep 16, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −34.0K | $96.49 | $3.3M | Sep 15, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −41.0K | $99.45 | $4.1M | Sep 14, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −45.0K | $96.93 | $4.4M | Sep 11, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −20.5K | $96.31 | $2.0M | Sep 10, 2026 | Form 4 ↗ |
| Sahin UgurChief Executive Officer | Sale | −36.0K | $97.78 | $3.5M | Sep 9, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding BNTX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Fidelity Contrafund | 3.3M | $305.0M | 0.17% | Jun 30, 2026 |
| Dodge & Cox International Stock Fund Dodge & Cox Funds | 2.5M | $234.3M | 0.35% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund T. Rowe Price Capital Appreciation Fund, Inc. | 2.3M | $202.0M | 0.31% | Mar 31, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 1.0M | $94.8M | 0.41% | Jun 30, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund PRIMECAP Odyssey Funds | 897.2K | $81.3M | 1.10% | Jul 31, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund | 794.7K | $73.9M | 2.63% | Jun 30, 2026 |
| Fidelity Contrafund K6 Fidelity Contrafund | 704.5K | $65.6M | 0.17% | Jun 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 647.1K | $60.2M | 0.66% | Jun 30, 2026 |
| Fidelity Emerging Markets Fund Fidelity Investment Trust | 660.8K | $59.9M | 0.55% | Jul 31, 2026 |
| Dodge & Cox Global Stock Fund Dodge & Cox Funds | 525.8K | $48.9M | 0.38% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list BNTX's shares (CUSIP 09075V102), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming BioNTech SE as client
No lobbying filings found naming BioNTech SE as the client.
Government Contracts
Federal awards to BioNTech SE · USAspending
No federal contract awards found for BioNTech SE.
U.S. Patents
Recent USPTO applications naming BioNTech SE
No USPTO patent applications found for BioNTech SE.
Annual Financials
From BNTX's 10-K filings · XBRL
No annual XBRL figures on record for BNTX. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in BNTX's price history.
Material Events (8-K)
Corporate events filed with the SEC
No 8-K filings on record.
About BioNTech SE
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersMAINZ, Germany
Incorporated2M
SEC CIK0001776985 ↗